世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の点眼薬市場予測 2019-2027年

GLOBAL OPHTHALMIC DRUG MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2019年6月US$2,500
シングルユーザライセンス(印刷不可PDF)
124

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートは世界の点眼薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS

The global ophthalmic drugs market is anticipated to grow at a CAGR of 4.31% between 2019 and 2027 to generate revenue of $38,473 million by 2027. An existing predominance and increase in the number of eye disorders with a growing geriatric population all over the world are the primary drivers responsible for market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.
MARKET INSIGHTS
The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. Vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause of half-blindness and decreased vision is the cataract, which has the highest percentage accountable for worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted consumer spending, thus indirectly driving the ophthalmic drugs market.

REGIONAL INSIGHTS

North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for the second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in the aged population and the existence of dominant market players in the regions are driving the regional markets.
COMPETITIVE INSIGHTS
The predominant ophthalmic drugs companies in the global market are Bayer, Allergan Inc., Sun Pharmaceuticals Industries, Ltd., Valeant, GlaxoSmithKline, Apollo Endosurgery, Regeneron, Senju Pharmaceutical Co., Ltd., Abbott Laboratories, Merck & Co., Novartis AG, Roche Holding AG, Pfizer Inc., Cipla Pharmaceuticals, Eyegate Pharmaceuticals, and Johnson and Johnson.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2.

KEY FINDINGS

3.2.1. RETINAL DISORDERS ARE THE HIGHEST REVENUE GENERATING INDICATION
3.2.2. PRESCRIPTION DRUGS ARE THE FASTEST GROWING OPHTHALMIC DRUGS TYPE
3.2.3. HOSPITAL PHARMACIES ARE THE MAJORLY USED DISTRIBUTION CHANNEL
3.2.4. LIQUID OPHTHALMIC DRUG FORMS ARE THE WIDELY USED DOSAGE FORM
3.2.5. ANTI-ALLERGY THERAPEUTIC CLASS IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD
3.2.6. SMALL MOLECULE TECHNOLOGY IS USED FOR THE TREATMENT OF EYE DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DEFINITION AND SCOPE
4.2. MARKET DRIVERS
4.2.1. INCREASING GERIATRIC POPULATION
4.2.2. TECHNOLOGICAL ADVANCEMENT
4.2.3. RISING PREVALENCE OF EYE DISORDERS
4.2.4. INCREASED HEALTHCARE EXPENDITURE
4.3. MARKET RESTRAINTS
4.3.1. RENOWNED DRUGS GOING OFF-PATENT
4.3.2. DELAY IN DRUG APPROVALS
4.4. MARKET OPPORTUNITIES
4.4.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.4.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
4.5. MARKET CHALLENGES
4.5.1. SIDE EFFECTS RELATED TO THE OPHTHALMIC DRUGS
5. MARKET BY INDICATION
5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGY
5.4. RETINAL DISORDERS
5.4.1. WET AGE-RELATED MACULAR DEGENERATION
5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
5.4.3. DIABETIC RETINOPATHY
5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATION
6. MARKET BY TYPE
6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. DRUG STORES
7.3. ONLINE PHARMACIES
7.4. OTHER DISTRIBUTION CHANNEL
8. MARKET BY DOSAGE FORM
8.1. LIQUID OPHTHALMIC DRUG FORMS
8.2. SOLID OPHTHALMIC DRUG FORMS
8.3. SEMISOLID OPHTHALMIC DRUG FORMS
8.4. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
8.5. OTHER OPHTHALMIC DRUG FORMS
9. MARKET BY THERAPEUTIC CLASS
9.1. ANTI-GLAUCOMA
9.2. ANTI-INFECTIVE
9.3. ANTI-INFLAMMATORY
9.4. ANTI-ALLERGY
10. MARKET BY TECHNOLOGY
10.1. BIOLOGICS
10.2. CELL THERAPY
10.3. GENE THERAPY
10.4. DRUG DELIVERY
10.5. SMALL MOLECULE
10.6. OTHER TECHNOLOGY
11. KEY ANALYTICS
11.1. PORTER’S FIVE FORCES ANALYSIS
11.1.1. BARGAINING POWER OF BUYERS
11.1.2. BARGAINING POWER OF SUPPLIER
11.1.3. THREATS OF NEW ENTRANTS
11.1.4. THREATS OF SUBSTITUTES
11.1.5. COMPETITIVE RIVALRY
11.2. VALUE CHAIN ANALYSIS
11.2.1. RESEARCH AND DEVELOPMENT
11.2.2. MANUFACTURING
11.2.3. MARKETING AND DISTRIBUTION
11.3. REGULATORY FRAMEWORK
11.4. OPPORTUNITY MATRIX
12. GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1. THE UNITED STATES
12.1.2. CANADA
12.2. EUROPE
12.2.1. GERMANY
12.2.2. THE UNITED KINGDOM
12.2.3. FRANCE
12.2.4. ITALY
12.2.5. SPAIN
12.2.6. REST OF EUROPE
12.3. ASIA PACIFIC
12.3.1. CHINA
12.3.2. INDIA
12.3.3. JAPAN
12.3.4. SOUTH KOREA
12.3.5. AUSTRALIA
12.3.6. REST OF ASIA PACIFIC
12.4. REST OF WORLD
12.4.1. MIDDLE EAST & AFRICA
12.4.2. LATIN AMERICA
13. COMPANY PROFILES
13.1. ABBOTT LABORATORIES
13.2. ALLERGAN INC.
13.3. JOHNSON AND JOHNSON
13.4. BAYER
13.5. VALEANT
13.6. REGENERON
13.7. PFIZER INC.
13.8. MERCK & CO.
13.9. NOVARTIS AG
13.10. GLAXOSMITHKLINE
13.11. EYEGATE PHARMACEUTICALS
13.12. APOLLO ENDOSURGERY
13.13. ROCHE HOLDING AG
13.14. CIPLA PHARMACEUTICALS
13.15. SENJU PHARMACEUTICAL CO., LTD.
13.16. SUN PHARMACEUTICALS INDUSTRIES, LTD.


LIST OF TABLES
TABLE 1 GLOBAL OPHTHALMIC DRUG MARKET REVENUE BY REGION 2019-2027 ($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 5 GLOBAL DRY EYE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 6 GLOBAL OPHTHALMIC DRUGS MARKET BY DRY EYE 2019-2027 ($ MILLION)
TABLE 7 GLOBAL GLAUCOMA MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 8 GLOBAL INFECTION/INFLAMMATION/ALLERGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 9 GLOBAL RETINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 10 GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 12 GLOBAL DIABETIC RETINOPATHY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 13 GLOBAL OTHER RETINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 14 GLOBAL OTHER INDICATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 15 GLOBAL OPHTHALMIC DRUGS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 16 GLOBAL PRESCRIPTION DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 17 GLOBAL OVER-THE-COUNTER DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 18 GLOBAL OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
TABLE 19 GLOBAL HOSPITAL PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 20 GLOBAL DRUG STORES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 21 GLOBAL ONLINE PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 22 GLOBAL OTHER DISTRIBUTION CHANNEL MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 23 GLOBAL OPHTHALMIC DRUGS MARKET BY DOSAGE FORM 2019-2027 ($ MILLION)
TABLE 24 GLOBAL LIQUID OPHTHALMIC DRUG FORMS PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 25 GLOBAL SOLID OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 26 GLOBAL SEMISOLID OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 27 GLOBAL MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 28 GLOBAL OTHER OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 29 GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTIC CLASS 2019-2027 ($ MILLION)
TABLE 30 GLOBAL ANTI-GLAUCOMA MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 31 GLOBAL ANTI-INFECTIVE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 32 GLOBAL ANTI-INFLAMMATORY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 33 GLOBAL ANTI-ALLERGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 34 GLOBAL OPHTHALMIC DRUGS MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 35 GLOBAL BIOLOGICS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 36 GLOBAL CELL THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 37 GLOBAL GENE THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 38 GLOBAL DRUG DELIVERY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 39 GLOBAL SMALL MOLECULE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 40 GLOBAL OTHER TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 41 GLOBAL OPHTHALMIC DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 42 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 43 EUROPE OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 44 ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES
FIGURE 1 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
FIGURE 5 HEALTHCARE EXPENDITURE CATARACT SURGERIES ON THE RISE
FIGURE 6 GLOBAL OPHTHALMIC DRUGS MARKET BY GLAUCOMA2019-2027 ($ MILLION)
FIGURE 7 GLOBAL OPHTHALMIC DRUGS MARKET BY INFECTION/ INFLAMMATION/ ALLERGY 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY RETINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL RETINAL DISORDERS MARKET BY WET AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL RETINAL DISORDERS MARKET BY DRY AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL RETINAL DISORDERS MARKET BY DIABETIC RETINOPATHY 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL RETINAL DISORDERS MARKET BY OTHER RETINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER INDICATION 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION DRUGS 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL OPHTHALMIC DRUGS MARKET BY OVER-THE-COUNTER DRUGS 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL OPHTHALMIC DRUGS MARKET BY HOSPITAL PHARMACIES 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG STORES 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL OPHTHALMIC DRUGS MARKET BY ONLINE PHARMACIES 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL OPHTHALMIC DRUGS MARKET BY LIQUID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL OPHTHALMIC DRUGS MARKET BY SOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL OPHTHALMIC DRUGS MARKET BY SEMISOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL OPHTHALMIC DRUGS MARKET BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 25 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-GLAUCOMA 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-INFECTIVE 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-INFLAMMATORY 2019-2027 ($ MILLION)
FIGURE 28 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-ALLERGY 2019-2027 ($ MILLION)
FIGURE 29 GLOBAL OPHTHALMIC DRUGS MARKET BY BIOLOGICS 2019-2027 ($ MILLION)
FIGURE 30 GLOBAL OPHTHALMIC DRUGS MARKET BY CELL THERAPY 2019-2027 ($ MILLION)
FIGURE 31 GLOBAL OPHTHALMIC DRUGS MARKET BY GENE THERAPY 2019-2027 ($ MILLION)
FIGURE 32 GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG DELIVERY 2019-2027 ($ MILLION)
FIGURE 33 GLOBAL OPHTHALMIC DRUGS MARKET BY SMALL MOLECULE 2019-2027 ($ MILLION)
FIGURE 34 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 35 THE UNITED STATES POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
FIGURE 36 THE UNITED STATES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 37 CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 38 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
FIGURE 39 EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 40 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
FIGURE 41 GERMANY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 42 THE UNITED KINGDOM OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 43 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
FIGURE 44 POPULATION AGED 65 AND ABOVE IN FRANCE (% OF TOTAL)
FIGURE 45 FRANCE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 46 ITALY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 47 SPAIN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 48 REST OF EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 49 ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 50 CHINA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 51 INDIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 52 JAPAN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 53 SOUTH KOREA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 54 NUMBER OF YEARS FOR PERCENTAGE, AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 55 AUSTRALIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 56 REST OF ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 57 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 58 LATIN AMERICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 59 AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)

List of Tables

LIST OF TABLES
TABLE 1 GLOBAL OPHTHALMIC DRUG MARKET REVENUE BY REGION 2019-2027 ($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
TABLE 5 GLOBAL DRY EYE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 6 GLOBAL OPHTHALMIC DRUGS MARKET BY DRY EYE 2019-2027 ($ MILLION)
TABLE 7 GLOBAL GLAUCOMA MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 8 GLOBAL INFECTION/INFLAMMATION/ALLERGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 9 GLOBAL RETINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 10 GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 12 GLOBAL DIABETIC RETINOPATHY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 13 GLOBAL OTHER RETINAL DISORDERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 14 GLOBAL OTHER INDICATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 15 GLOBAL OPHTHALMIC DRUGS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 16 GLOBAL PRESCRIPTION DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 17 GLOBAL OVER-THE-COUNTER DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 18 GLOBAL OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
TABLE 19 GLOBAL HOSPITAL PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 20 GLOBAL DRUG STORES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 21 GLOBAL ONLINE PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 22 GLOBAL OTHER DISTRIBUTION CHANNEL MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 23 GLOBAL OPHTHALMIC DRUGS MARKET BY DOSAGE FORM 2019-2027 ($ MILLION)
TABLE 24 GLOBAL LIQUID OPHTHALMIC DRUG FORMS PHARMACIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 25 GLOBAL SOLID OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 26 GLOBAL SEMISOLID OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 27 GLOBAL MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 28 GLOBAL OTHER OPHTHALMIC DRUG FORMS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 29 GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTIC CLASS 2019-2027 ($ MILLION)
TABLE 30 GLOBAL ANTI-GLAUCOMA MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 31 GLOBAL ANTI-INFECTIVE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 32 GLOBAL ANTI-INFLAMMATORY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 33 GLOBAL ANTI-ALLERGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 34 GLOBAL OPHTHALMIC DRUGS MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 35 GLOBAL BIOLOGICS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 36 GLOBAL CELL THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 37 GLOBAL GENE THERAPY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 38 GLOBAL DRUG DELIVERY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 39 GLOBAL SMALL MOLECULE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 40 GLOBAL OTHER TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 41 GLOBAL OPHTHALMIC DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 42 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 43 EUROPE OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 44 ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

List of Figures

LIST OF FIGURES
FIGURE 1 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
FIGURE 5 HEALTHCARE EXPENDITURE CATARACT SURGERIES ON THE RISE
FIGURE 6 GLOBAL OPHTHALMIC DRUGS MARKET BY GLAUCOMA2019-2027 ($ MILLION)
FIGURE 7 GLOBAL OPHTHALMIC DRUGS MARKET BY INFECTION/ INFLAMMATION/ ALLERGY 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY RETINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL RETINAL DISORDERS MARKET BY WET AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL RETINAL DISORDERS MARKET BY DRY AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL RETINAL DISORDERS MARKET BY DIABETIC RETINOPATHY 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL RETINAL DISORDERS MARKET BY OTHER RETINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER INDICATION 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION DRUGS 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL OPHTHALMIC DRUGS MARKET BY OVER-THE-COUNTER DRUGS 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL OPHTHALMIC DRUGS MARKET BY HOSPITAL PHARMACIES 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG STORES 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL OPHTHALMIC DRUGS MARKET BY ONLINE PHARMACIES 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL OPHTHALMIC DRUGS MARKET BY LIQUID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL OPHTHALMIC DRUGS MARKET BY SOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL OPHTHALMIC DRUGS MARKET BY SEMISOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL OPHTHALMIC DRUGS MARKET BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)
FIGURE 25 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-GLAUCOMA 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-INFECTIVE 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-INFLAMMATORY 2019-2027 ($ MILLION)
FIGURE 28 GLOBAL OPHTHALMIC DRUGS MARKET BY ANTI-ALLERGY 2019-2027 ($ MILLION)
FIGURE 29 GLOBAL OPHTHALMIC DRUGS MARKET BY BIOLOGICS 2019-2027 ($ MILLION)
FIGURE 30 GLOBAL OPHTHALMIC DRUGS MARKET BY CELL THERAPY 2019-2027 ($ MILLION)
FIGURE 31 GLOBAL OPHTHALMIC DRUGS MARKET BY GENE THERAPY 2019-2027 ($ MILLION)
FIGURE 32 GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG DELIVERY 2019-2027 ($ MILLION)
FIGURE 33 GLOBAL OPHTHALMIC DRUGS MARKET BY SMALL MOLECULE 2019-2027 ($ MILLION)
FIGURE 34 GLOBAL OPHTHALMIC DRUGS MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 35 THE UNITED STATES POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
FIGURE 36 THE UNITED STATES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 37 CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 38 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
FIGURE 39 EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 40 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
FIGURE 41 GERMANY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 42 THE UNITED KINGDOM OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 43 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
FIGURE 44 POPULATION AGED 65 AND ABOVE IN FRANCE (% OF TOTAL)
FIGURE 45 FRANCE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 46 ITALY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 47 SPAIN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 48 REST OF EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 49 ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 50 CHINA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 51 INDIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 52 JAPAN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 53 SOUTH KOREA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 54 NUMBER OF YEARS FOR PERCENTAGE, AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 55 AUSTRALIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 56 REST OF ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 57 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 58 LATIN AMERICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 59 AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る